itopride has been researched along with Dyspepsia in 26 studies
Dyspepsia: Impaired digestion, especially after eating.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulpiride and itopride are effective in the treatment of dyspepsia in the form of postprandial distress syndrome." | 9.19 | [Efficacy of sulpiride and itopride in the treatment of functional dyspepsia in women with emotional and eating disorders]. ( Chojnacki, C; Klupińska, G; Pawłowicz, M; Wachowska-Kelly, P; Walecka-Kapica, E; Wojtkiewicz, P, 2014) |
| "To evaluate the efficacy and safety of itopride used to treat the symptoms of functional dyspepsia (FD) of the upper gastrointestinal tract." | 9.19 | [Use of itopride in the symptoms of functional dyspepsia in Russia: results of a phase IV prospective open-label multicenter clinical trial]. ( Denisov, NL; Kas'ianenko, VI; Vasil'ev, IuV, 2014) |
| "Patients with functional dyspepsia were randomly assigned to receive either itopride (50, 100, or 200 mg three times daily) or placebo." | 9.12 | A placebo-controlled trial of itopride in functional dyspepsia. ( Adam, B; Holtmann, G; Liebregts, T; Parow, C; Talley, NJ, 2006) |
| "After administration of itopride hydrochloride, the SF-36 mental health scale and GSRS indigestion syndrome score and constipation syndrome score were significantly improved compared to before administration (p < 0." | 9.12 | Effects of itopride hydrochloride and ranitidine in patients with functional dyspepsia: comparison between prokinetic and acid suppression therapies. ( Chiba, T; Chishima, R; Endo, M; Ikeda, K; Inomata, M; Kudara, N; Orii, S; Suzuki, K; Takagi, R; Terui, T; Tokunaga, Y, 2007) |
| "Prokinetic agents like itopride hydrochloride and mosapride citrate are commonly used in the management of functional dyspepsia." | 9.11 | Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. ( Amarapurkar, DN; Rane, P, 2004) |
| "To document the clinical efficacy and tolerability of itopride hydrochloride in patients with non-ulcer dyspepsia an open-label, non-comparative study, was undertaken at the Medical College, Thiruvananthapuram, among patients with endoscopically confirmed diagnosis of non-ulcer dyspepsia or chronic gastritis." | 9.10 | Efficacy and tolerability of itopride hydrochloride in patients with non-ulcer dyspepsia. ( Leena, KB; Shenoy, KT, 2003) |
| "To evaluate the therapeutic effects of itopride vs other drugs (placebo, domperidone, mosapride) for functional dyspepsia (FD)." | 8.88 | Itopride therapy for functional dyspepsia: a meta-analysis. ( Fan, YH; Huang, X; Lv, B; Meng, LN; Zhang, S, 2012) |
| "Itopride is a novel prokinetic agent with a dual mode of action, good safety profile and documented efficacy in placebo-controlled trials." | 5.37 | Itopride in the treatment of functional dyspepsia in Chinese patients: a prospective, multicentre, post-marketing observational study. ( Holtmann, G; Sun, J; Yuan, YZ, 2011) |
| "Sulpiride and itopride are effective in the treatment of dyspepsia in the form of postprandial distress syndrome." | 5.19 | [Efficacy of sulpiride and itopride in the treatment of functional dyspepsia in women with emotional and eating disorders]. ( Chojnacki, C; Klupińska, G; Pawłowicz, M; Wachowska-Kelly, P; Walecka-Kapica, E; Wojtkiewicz, P, 2014) |
| "To evaluate the efficacy and safety of itopride used to treat the symptoms of functional dyspepsia (FD) of the upper gastrointestinal tract." | 5.19 | [Use of itopride in the symptoms of functional dyspepsia in Russia: results of a phase IV prospective open-label multicenter clinical trial]. ( Denisov, NL; Kas'ianenko, VI; Vasil'ev, IuV, 2014) |
| "The aim of the study was to evaluate and document the efficacy and tolerability of rabeto plus (FDC of rabeprazole and itopride) in management of functional dyspepsia." | 5.13 | Rabeto plus: a valuable drug for managing functional dyspepsia. ( Basu, M; Dabholkar, P; Ghosh, A; Halder, S; Mandal, A; Mandal, S, 2008) |
| "Patients with functional dyspepsia were randomly assigned to receive either itopride (50, 100, or 200 mg three times daily) or placebo." | 5.12 | A placebo-controlled trial of itopride in functional dyspepsia. ( Adam, B; Holtmann, G; Liebregts, T; Parow, C; Talley, NJ, 2006) |
| "After administration of itopride hydrochloride, the SF-36 mental health scale and GSRS indigestion syndrome score and constipation syndrome score were significantly improved compared to before administration (p < 0." | 5.12 | Effects of itopride hydrochloride and ranitidine in patients with functional dyspepsia: comparison between prokinetic and acid suppression therapies. ( Chiba, T; Chishima, R; Endo, M; Ikeda, K; Inomata, M; Kudara, N; Orii, S; Suzuki, K; Takagi, R; Terui, T; Tokunaga, Y, 2007) |
| "Prokinetic agents like itopride hydrochloride and mosapride citrate are commonly used in the management of functional dyspepsia." | 5.11 | Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. ( Amarapurkar, DN; Rane, P, 2004) |
| "To document the clinical efficacy and tolerability of itopride hydrochloride in patients with non-ulcer dyspepsia an open-label, non-comparative study, was undertaken at the Medical College, Thiruvananthapuram, among patients with endoscopically confirmed diagnosis of non-ulcer dyspepsia or chronic gastritis." | 5.10 | Efficacy and tolerability of itopride hydrochloride in patients with non-ulcer dyspepsia. ( Leena, KB; Shenoy, KT, 2003) |
| "To evaluate the therapeutic effects of itopride vs other drugs (placebo, domperidone, mosapride) for functional dyspepsia (FD)." | 4.88 | Itopride therapy for functional dyspepsia: a meta-analysis. ( Fan, YH; Huang, X; Lv, B; Meng, LN; Zhang, S, 2012) |
| "Mosapride citrate (mosapride), a prokinetic agent with 5-HT(4)-receptor agonistic activity, is known to enhance gastric emptying and alleviate symptoms in patients with functional dyspepsia (FD)." | 3.77 | Effects of mosapride citrate, a 5-HT4-receptor agonist, on gastric distension-induced visceromotor response in conscious rats. ( Kaneko, H; Seto, Y; Yoshida, N, 2011) |
| " The scope of the fluorous N-O linker is exemplified by the synthesis of itopride, a drug used for the treatment of functional dyspepsia." | 3.76 | Synthesis and application of a new fluorous-tagged ammonia equivalent. ( Begtrup, M; Kristensen, JL; Nielsen, SD; Smith, G, 2010) |
| "Itopride is a new safer prokinetic drug with dopamine D2 antagonism and acetylcholinesterase inhibitory actions." | 2.71 | Evaluation of new gastro-intestinal prokinetic (ENGIP-II) study. ( Bargaje, RS; Kulkarni, SS; Walwaikar, PP, 2005) |
| "Dyspepsia is a common condition associated with gastrointestinal (GI) disease." | 2.58 | Prokinetics for functional dyspepsia. ( Bollegala, NP; Khanna, R; Leontiadis, GI; Moayyedi, P; Pittayanon, R; Yuan, Y, 2018) |
| "Itopride is a novel prokinetic agent with a dual mode of action, good safety profile and documented efficacy in placebo-controlled trials." | 1.37 | Itopride in the treatment of functional dyspepsia in Chinese patients: a prospective, multicentre, post-marketing observational study. ( Holtmann, G; Sun, J; Yuan, YZ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (46.15) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Carbone, F | 1 |
| Vandenberghe, A | 1 |
| Holvoet, L | 1 |
| Piessevaux, H | 1 |
| Arts, J | 1 |
| Caenepeel, P | 1 |
| Staessen, D | 1 |
| Vergauwe, P | 1 |
| Maldague, P | 1 |
| De Ronde, T | 1 |
| Wuestenberghs, F | 1 |
| Lamy, V | 1 |
| Lefebvre, V | 1 |
| Latour, P | 1 |
| Vanuytsel, T | 1 |
| Jones, M | 1 |
| Tack, J | 2 |
| Hashimoto, K | 1 |
| Tashima, K | 1 |
| Imai, T | 1 |
| Matsumoto, K | 1 |
| Horie, S | 1 |
| Yang, YJ | 1 |
| Bang, CS | 1 |
| Baik, GH | 1 |
| Park, TY | 1 |
| Shin, SP | 1 |
| Suk, KT | 1 |
| Kim, DJ | 1 |
| Pittayanon, R | 1 |
| Yuan, Y | 1 |
| Bollegala, NP | 1 |
| Khanna, R | 1 |
| Leontiadis, GI | 1 |
| Moayyedi, P | 1 |
| Wachowska-Kelly, P | 1 |
| Walecka-Kapica, E | 1 |
| Wojtkiewicz, P | 1 |
| Pawłowicz, M | 1 |
| Klupińska, G | 1 |
| Chojnacki, C | 1 |
| Kas'ianenko, VI | 1 |
| Denisov, NL | 1 |
| Vasil'ev, IuV | 1 |
| Lan, L | 1 |
| Zeng, F | 1 |
| Liu, GJ | 1 |
| Ying, L | 1 |
| Wu, X | 1 |
| Liu, M | 1 |
| Liang, FR | 1 |
| Ito, K | 1 |
| Kawachi, M | 1 |
| Matsunaga, Y | 1 |
| Hori, Y | 1 |
| Ozaki, T | 1 |
| Nagahama, K | 1 |
| Hirayama, M | 1 |
| Kawabata, Y | 1 |
| Shiraishi, Y | 1 |
| Takei, M | 1 |
| Tanaka, T | 1 |
| Ghosh, A | 1 |
| Halder, S | 1 |
| Mandal, S | 1 |
| Mandal, A | 1 |
| Basu, M | 1 |
| Dabholkar, P | 1 |
| Nielsen, SD | 1 |
| Smith, G | 1 |
| Begtrup, M | 1 |
| Kristensen, JL | 1 |
| Seto, Y | 1 |
| Yoshida, N | 1 |
| Kaneko, H | 1 |
| Sun, J | 1 |
| Yuan, YZ | 1 |
| Holtmann, G | 2 |
| Hirata, T | 1 |
| Keto, Y | 1 |
| Yamano, M | 1 |
| Yokoyama, T | 1 |
| Sengoku, T | 1 |
| Seki, N | 1 |
| Lim, HC | 1 |
| Lee, SI | 1 |
| Chen, JD | 1 |
| Park, H | 1 |
| Huang, X | 1 |
| Lv, B | 1 |
| Zhang, S | 1 |
| Fan, YH | 1 |
| Meng, LN | 1 |
| Shenoy, KT | 1 |
| Leena, KB | 1 |
| Sawant, P | 1 |
| Das, HS | 1 |
| Desai, N | 1 |
| Kalokhe, S | 1 |
| Patil, S | 1 |
| Amarapurkar, DN | 1 |
| Rane, P | 1 |
| Talley, NJ | 2 |
| Liebregts, T | 1 |
| Adam, B | 1 |
| Parow, C | 1 |
| Taylor, KM | 1 |
| Harris, AW | 1 |
| Walwaikar, PP | 1 |
| Kulkarni, SS | 1 |
| Bargaje, RS | 1 |
| Kreutzkamp, B | 1 |
| Hiyama, T | 1 |
| Yoshihara, M | 1 |
| Matsuo, K | 1 |
| Kusunoki, H | 1 |
| Kamada, T | 1 |
| Ito, M | 1 |
| Tanaka, S | 1 |
| Nishi, N | 1 |
| Chayama, K | 1 |
| Haruma, K | 1 |
| Ptak, T | 1 |
| Gupta, R | 1 |
| Giguère, M | 1 |
| Chiba, T | 1 |
| Tokunaga, Y | 1 |
| Ikeda, K | 1 |
| Takagi, R | 1 |
| Chishima, R | 1 |
| Terui, T | 1 |
| Kudara, N | 1 |
| Endo, M | 1 |
| Inomata, M | 1 |
| Orii, S | 1 |
| Suzuki, K | 1 |
| Veldhuyzen Van Zanten, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Validation of a Questionnaire for Symptom Assessment in Postprandial Distress Syndrome (Functional Dyspepsia)[NCT04647955] | Phase 4 | 100 participants (Actual) | Interventional | 2013-02-22 | Completed | ||
| A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Dose Finding Study in 4 Parallel Groups to Establish the Efficacy and Safety of an Eight Week Treatment With Itopride Three Times Daily Compared to Placebo in Patients Suffering From Functional [NCT00272103] | Phase 2/Phase 3 | 500 participants | Interventional | 2000-12-31 | Completed | ||
| Self-Administered Hypnotherapy for Functional Dyspepsia[NCT03884270] | 23 participants (Actual) | Interventional | 2019-05-03 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Feasibility will be calculated as the proportion of participants who complete the hypnotherapy treatment program in comparison to those who drop out before treatment is completed. (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Hypnotherapy | 22 |
The BSI is an 18-item self-report questionnaire with responses on a 5-point Likert scale, ranging from 0 (not bothered by a symptom at all) to 4 (extremely bothered). Three subscales are calculated (somatization, depression, and anxiety) and the subscales can be aggregated to calculate an overall global psychological distress score. The overall score and subscale scores are converted to T-scores (with a population mean of 50 and a standard deviation of 10). Higher T-scores indicate more psychological distress and T-scores ≥63 indicate clinically significant psychological distress. The BSI score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -9.22 |
The PAGI-SYM is a 20-item self-report measure of functional dyspepsia symptom severity. The scale consists of 6 subscales (heartburn/regurgitation, nausea/vomiting, postprandial fullness/early satiety, bloating, upper abdominal pain, and lower abdominal pain). Each item is measured by a 6-point Likert scale ranging from 0 (no complaints) to 5 (severe complaints). Subscale scores are calculated by taking the mean of the items in each subscale. The total score is calculated by taking the mean of the subscale scores. Total scores range from 0 to 5, with higher scores indicating worse symptoms. The PAGI-SYM total score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3-months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -0.82 |
The NDI-SF is a 10-item self-report disease specific quality of life questionnaire. The scale consists of 5 sub-scales (tension/anxiety, interference with daily activities, disruption to regular eating/drinking, knowledge towards/control over disease, interference with work/study). Each item is measured by a 5-point Likert scale ranging from 0 (not applicable) to 4 (extremely). Individual items are aggregated to obtain a total score ranging from 0 to 100 with higher scores indicating greater impairment in quality of life. The NDI-SF score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -9.65 |
The VSI is a 15-item self-report questionnaire with responses ranging from 1 (strongly agree) to 6 (strongly disagree). The raw VSI score ranges from 0 (severe anxiety) to 75 (no anxiety). The VSI score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | 10.39 |
At both baseline and end of treatment, patients will be asked to report the number of outpatient visits and procedures they have had within the last 3 months related to their functional dyspepsia symptoms (NCT03884270)
Timeframe: Baseline, 12 weeks
| Intervention | number of events (Median) | |||
|---|---|---|---|---|
| Number of outpatient visits at baseline | Number of outpatient visits at end of treatment | Number of procedures at baseline | Number of procedures at end of treatment | |
| Hypnotherapy | 2 | 1 | 2 | 1 |
At baseline and end of treatment, patients will be asked to report any medications they are taking related to their functional dyspepsia symptoms. (NCT03884270)
Timeframe: Baseline, 12 weeks
| Intervention | number of medications (Median) | |
|---|---|---|
| Medications taking at baseline | Medications taking at end of treatment | |
| Hypnotherapy | 1 | 1 |
"At the end of treatment, patients were asked an open-ended question to obtain feedback on their experience using the web-based platform for treatment. They were asked to rate their difficulty using the web platform on a 7-point scale from Extremely difficult to Extremely easy." (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Extremely easy | Moderately easy | Somewhat easy | Neutral | Somewhat difficult | Moderately difficult | Extremely difficult | |
| Hypnotherapy | 17 | 3 | 1 | 1 | 0 | 0 | 0 |
"Treatment satisfaction will be assessed with a single item at the end of treatment asking how satisfied they were overall with their assigned treatment (on a 7-point scale from Extremely dissatisfied to Extremely satisfied)" (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Extremely dissatisfied | Very dissatisfied | Somewhat dissatisfied | Neutral | Somewhat satisfied | Very satisfied | Extremely satisfied | |
| Hypnotherapy | 1 | 0 | 0 | 2 | 12 | 4 | 3 |
6 reviews available for itopride and Dyspepsia
| Article | Year |
|---|---|
Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Bayes Theorem; Benzamides; Benzyl Compounds | 2017 |
Prokinetics for functional dyspepsia.
Topics: Benzamides; Benzyl Compounds; Cisapride; Domperidone; Dyspepsia; Erythromycin; Gastrointestinal Agen | 2018 |
Acupuncture for functional dyspepsia.
Topics: Acupuncture Therapy; Benzamides; Benzyl Compounds; Cisapride; Domperidone; Dyspepsia; Electroacupunc | 2014 |
Itopride therapy for functional dyspepsia: a meta-analysis.
Topics: Antiemetics; Benzamides; Benzyl Compounds; Domperidone; Dyspepsia; Gastrointestinal Agents; Humans; | 2012 |
Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia.
Topics: Benzamides; Benzyl Compounds; Cisapride; Domperidone; Dopamine Antagonists; Dyspepsia; Gastrointesti | 2007 |
Pitfalls in designing trials of functional dyspepsia: the ascent and demise of itopride.
Topics: Benzamides; Benzyl Compounds; Clinical Trials as Topic; Dyspepsia; Gastrointestinal Agents; Humans; | 2008 |
12 trials available for itopride and Dyspepsia
| Article | Year |
|---|---|
A double-blind randomized, multicenter, placebo-controlled study of itopride in functional dyspepsia postprandial distress syndrome.
Topics: Abdominal Pain; Benzamides; Benzyl Compounds; Dyspepsia; Female; Humans; Male; Postprandial Period; | 2022 |
[Efficacy of sulpiride and itopride in the treatment of functional dyspepsia in women with emotional and eating disorders].
Topics: Aged; Anxiety Disorders; Benzamides; Benzyl Compounds; Depression; Dopamine Antagonists; Dyspepsia; | 2014 |
[Use of itopride in the symptoms of functional dyspepsia in Russia: results of a phase IV prospective open-label multicenter clinical trial].
Topics: Acetylcholine; Benzamides; Benzyl Compounds; Cholinesterase Inhibitors; Dopamine Antagonists; Dopami | 2014 |
Rabeto plus: a valuable drug for managing functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzamides; Benzyl Compounds; Drug | 2008 |
Electrogastrography associated with symptomatic changes after prokinetic drug treatment for functional dyspepsia.
Topics: Adult; Aged; Benzamides; Benzyl Compounds; Dyspepsia; Electrodiagnosis; Female; Gastrointestinal Age | 2012 |
Efficacy and tolerability of itopride hydrochloride in patients with non-ulcer dyspepsia.
Topics: Adult; Benzamides; Benzyl Compounds; Dyspepsia; Female; Humans; Male; Middle Aged; Treatment Outcome | 2003 |
Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia.
Topics: Administration, Oral; Adolescent; Adult; Benzamides; Benzyl Compounds; Domperidone; Dose-Response Re | 2004 |
Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia.
Topics: Administration, Oral; Adult; Benzamides; Benzyl Compounds; Dose-Response Relationship, Drug; Double- | 2004 |
A placebo-controlled trial of itopride in functional dyspepsia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Benzyl Compounds; Dopamine D2 Receptor Antag | 2006 |
Evaluation of new gastro-intestinal prokinetic (ENGIP-II) study.
Topics: Acetylcholinesterase; Adult; Benzamides; Benzyl Compounds; Dopamine D2 Receptor Antagonists; Dyspeps | 2005 |
Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials.
Topics: Adolescent; Adult; Aged; Benzamides; Benzyl Compounds; Double-Blind Method; Dyspepsia; Female; Gastr | 2008 |
Effects of itopride hydrochloride and ranitidine in patients with functional dyspepsia: comparison between prokinetic and acid suppression therapies.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzamides; Benzyl Compounds; Dyspepsia; Female; Gastroesophageal Re | 2007 |
8 other studies available for itopride and Dyspepsia
| Article | Year |
|---|---|
The rodent model of impaired gastric motility induced by allyl isothiocyanate, a pungent ingredient of wasabi, to evaluate therapeutic agents for functional dyspepsia.
Topics: Animals; Benzamides; Benzyl Compounds; Disease Models, Animal; Dyspepsia; Gastrointestinal Motility; | 2021 |
Acotiamide Hydrochloride, a Therapeutic Agent for Functional Dyspepsia, Enhances Acetylcholine-induced Contraction via Inhibition of Acetylcholinesterase Activity in Circular Muscle Strips of Guinea Pig Stomach.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Benzamides; Benzyl Compounds; Carbachol; Cholinesteras | 2016 |
Synthesis and application of a new fluorous-tagged ammonia equivalent.
Topics: Amides; Ammonia; Benzamides; Benzyl Compounds; Carbamates; Combinatorial Chemistry Techniques; Dyspe | 2010 |
Effects of mosapride citrate, a 5-HT4-receptor agonist, on gastric distension-induced visceromotor response in conscious rats.
Topics: Abdominal Pain; Analgesics, Non-Narcotic; Animals; Benzamides; Benzyl Compounds; Dose-Response Relat | 2011 |
Itopride in the treatment of functional dyspepsia in Chinese patients: a prospective, multicentre, post-marketing observational study.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzamides; Benzyl Compounds; China; Drug Administrati | 2011 |
Inhibitory effect of ramosetron on corticotropin releasing factor- and soybean oil-induced delays in gastric emptying in rats.
Topics: Animals; Antidiarrheals; Benzamides; Benzimidazoles; Benzyl Compounds; Biguanides; Corticotropin-Rel | 2012 |
Itopride for functional dyspepsia.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzamides; Benzyl Compounds; D | 2006 |
[Functional dyspepsia. Itopride improves symptoms].
Topics: Antiemetics; Benzamides; Benzyl Compounds; Dopamine Antagonists; Dyspepsia; Humans; Randomized Contr | 2006 |